Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 06
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
ANI Pharmaceuticals Inc
ANIP
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$72.58
0.40
0.55%
Dern. MÀJ: Oct 5, 4:00 PM
$72.58
0.40
0.55%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
ANI Pharmaceuticals Financials
ANI Pharmaceuticals (ANIP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.
Avi Kapoor
PRO
ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est
ANI Pharmaceuticals (NASDAQ:ANIP) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080 billion-$1.140
Benzinga Newsdesk
PRO
ANI Pharmaceuticals Q2 Adj. EPS $2.21 Beats $2.05 Estimate, Sales $266.044M Beat $260.128M Estimate
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 by 7.8 percent. This is a 22.78 percent increase over earnings of $1.80 per share from
Benzinga Newsdesk
PRO
ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 Est; Raises FY2026 Sales Guidance from $1.055B-$1.115B to $1.080B-$1.140B vs $1.050B Est.
ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 analyst estimate. Raises FY2026 sales outlook from $1.055 billion-$1.115 billion to $1.080 billion-$1.140 billion
Benzinga Newsdesk
PRO
ANI Pharmaceuticals Q1 Adj. EPS $2.05 Beats $1.30 Estimate, Sales $237.462M Beat $207.565M Estimate.
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.30 by 56.49 percent. This is a 20.59 percent increase over earnings of $1.70 per share from
Benzinga Newsdesk
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
ANI Pharma beats Q4 estimates, swings to profit, and sees over $1 billion in 2026 sales as Rare Disease revenue surges 50%.
Vandana Singh
